Cognetivity Neurosciences’ (CSE:CGN; OTCQB:CGNSF) Integrated Cognitive Assessment (ICA) test is to form an integral part of a new and highly innovative clinic in the UK’s National Health Service (NHS) dedicated to...
The FDA’s Gastroenterology and Urology Devices Panel, after a review and discussion, issued a favorable vote in support of approval of TransMedics Group’s (NASDAQ:TMDX) OCS Liver System. The panel voted 14-to-0...
Closely held ENA Respiratory of Australia initiated a Phase 1 human safety study of INNA-051, being developed to activate innate immunity in the nose, the primary entry portal of most respiratory viral infections. A...
Mesosil, a closely held company developing the first lifetime-effect antimicrobial materials for dental and medical devices, closed an initial seed round of $675,000 led by the Archangel Network of Funds and NorthSpring...
Hepion Pharmaceuticals (NASDAQ:HEPA) reported that all primary endpoints were met in its Phase 2a AMBITION clinical trial in patients with non-alcoholic steatohepatitis (NASH). The Phase 2a trial was designed to...
Carrot Inc., a closely held digital health company, received expanded use indications for its Pivot Carbon Monoxide Breath Sensor in a new 510(k) clearance by the FDA based on published clinical trial data. As the only...
Lumos Diagnostics, with corporate head offices in Melbourne and U.S.-based R&D, commercial operations and manufacturing in both Florida and California, raised $63-million (Australian) in an initial public...
Advaxis (NASDAQ:ADXS) and closely held Biosight of Israel entered into a definitive merger agreement, with shareholders of Biosight becoming the majority holders of the combined company. Advaxis will be renamed Biosight...
Seelos Therapeutics (NASDAQ:SEEL) dosed the first patient in Part 2 of its registrational proof-of-concept study of SLS-002 (intranasal racemic ketamine) for acute suicidal ideation and behavior in patients with major...
UNITY Biotechnology (NASDAQ:UBX) announced positive data from its Phase 1 safety study of UBX1325 in patients with advanced disease from diabetic macular edema (DME) or wet age-related macular degeneration (AMD) for...